Relay Therapeutics (RLAY) Statistics

Relay Therapeutics Inc (RLAY) is a biotechnology company that focuses on discovering and developing small molecule drugs for the treatment of various diseases. The company utilizes its proprietary Dynamo platform, which combines computational modeling and experimental techniques to design novel drug candidates. RLAY stock statistics indicate that the company's shares are traded on the Nasdaq stock exchange under the ticker symbol RLAY. As of the latest available data, RLAY's market capitalization is valued at $2.5 billion.

When evaluating RLAY's valuation metrics, several factors come into play. For instance, the company's price-to-earnings ratio (P/E) is an essential metric that indicates how much investors are willing to pay for each dollar of RLAY's earnings. Additionally, RLAY's price-to-sales ratio (P/S) provides insights into how the market values the company's revenue. Other valuation metrics include price-to-book ratio (P/B), which evaluates the company's book value per share, and price-to-cash-flow ratio (P/CF), which assesses RLAY's ability to generate cash flow from its operations.